These results suggest that AR can be a potential target of CDK5 inhibition in regulating the growth of prostate cancer cells, and new small molecular compounds, like Dinaciclib, can be potentially developed as a potential treatment for prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.